New hope for rare blood disorder: drug targets overactive immune cells
Disease control
Recruiting now
This phase 2 trial is testing the drug ruxolitinib in people with hypereosinophilic syndrome, a rare condition where the body produces too many eosinophils (a type of white blood cell), causing organ damage. The study aims to see if ruxolitinib can normalize blood cell counts and…
Phase: PHASE2 • Sponsor: William Shomali • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC